Antiretroviral drug toxicity in human immunodeficiency virus infected children

Paediatric Human Immunodeficiency Virus infection (HIV) nowadays is a chronic disease with an excellent long term prognosis, but lifelong combined antiretroviral treatment is required. However, an improved quality of life in this population is limited by adverse drug effects. The highest risk of tre...

Full description

Saved in:
Bibliographic Details
Published in:Anales de pediatría (Barcelona, Spain : 2003) Spain : 2003), 2008-05, Vol.68 (5), p.425
Main Authors: Núñez Cuadros, E, Mellado Peña, M J, Rivera Cuello, M, Penim Fernández, M, Piñeiro Pérez, R, García-Hortelano, M, Cilleruelo Ortega, M J, Villota Arrieta, J, Martín-Fontelos, P
Format: Article
Language:Spanish
Subjects:
Acidosis, Lactic - chemically induced
Adolescent
Anti-Retroviral Agents - adverse effects
Bone Diseases, Metabolic - chemically induced
Bone Diseases, Metabolic - diagnostic imaging
Child
Child, Preschool
Female
HIV Infections - drug therapy
Humans
Hyperlipidemias - chemically induced
Hypertension - chemically induced
Insulin Resistance
Lipodystrophy - chemically induced
Metabolic Syndrome - chemically induced
Radiography
Zidovudine - adverse effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paediatric Human Immunodeficiency Virus infection (HIV) nowadays is a chronic disease with an excellent long term prognosis, but lifelong combined antiretroviral treatment is required. However, an improved quality of life in this population is limited by adverse drug effects. The highest risk of treatment toxicity is developing a complete metabolic syndrome including: Hyperlipemia, lipodystrophy, insulin resistance, lactic acidosis, osteopenia, hypertension, and specific system and organ toxicity, such as the kidney, liver, CNS or bone marrow. The risk of cardiovascular disease adult life and also definitive bone mass damage are the most significant metabolic costs that have to paid for increased survival. Most of these toxicities were able to be adequately treated but, pharmacological interferences, patient intolerance and the high number of drugs are the problems that limit the adherence to treatment, which is essential for a good therapeutical efficacy. In this article, we present four HIV paediatric patients who presented with almost the whole range of metabolic toxicities, and a practical overview of therapeutical management.
ISSN:1695-4033